PMID: 18706247Aug 19, 2008Paper

A proposal on auxiliary business insurance for peritoneal dialysis treatment

Chinese Medical Journal
Juan WangJi-qian Fang

Abstract

The peritoneal dialysis (PD) therapy for end stage renal disease (ESRD) is expensive. The main reason for non-acceptance onto dialysis programs is the great cost. In the present study, we design an auxiliary business insurance program to provide the potential ESRD patients who have no access to governmental medical insurance or can not afford the remaining part besides the limited reimbursement for peritoneal dialysis therapy. The information applied in this study was extracted from the medical records of 641 PD patients, who were treated in two dialysis centers of the first and the third teaching hospitals of the Peking University respectively. A collective risk model was employed to estimate the expenses on PD therapy. Survival analyses were performed to obtain the average survival time of PD patients and the average length of time from the onset of the primary disease to the beginning of PD. An annuity method was used to determine the pure premium. For chronic nephritis, diabetes mellitus and hyperpietic as primary diseases, the mean survival time +/- standard errors were (55.1 +/- 3.7) months, (38.9 +/- 3.2) months and (61.4 +/- 4.6) months respectively, and they were significantly different from each other (all P = 0.000)....Continue Reading

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Suzanne Watnick, Susan T Crowley
Journal of Acquired Immune Deficiency Syndromes : JAIDS
Mathieu BastardJean-François Etard
Kidney International. Supplement
Alfonso M Cueto-Manzano
© 2022 Meta ULC. All rights reserved